Henry Ford Cancer Institute Senior Leadership

The Henry Ford Cancer Institute is led by an esteemed group of physicians, clinicians, researchers, and advisors, each of whom do their part to ensure excellence in cancer care, education, and research.

Benjamin Movsas, M.D.
Interim Medical Director, Henry Ford Cancer Institute

Dr. Movsas serves as Chair, Department of Radiation Oncology and is an international expert in radiation oncology, and quality of life issues pertaining to cancer. He serves as the co-Chair of the National Cancer Institute (NCI) Patient Centered Outcomes Committee (PCOR) of the NRG cooperative group. He is recognized as a Fellow of the American Society of Radiation Oncology (ASTRO) and the American College of Radiology (ACR). He recently served as the President of the American Radium Society and is Chair of the Education Council on the ASTRO Board of Directors.

Madelyn Van Tassel
Interim Vice President and Executive Director, Henry Ford Cancer Institute

Madelyn has been with Henry Ford since 2010, most recent serving as Director of Cancer Care Pathways and the Director of Surgical Oncology Specialties for the Cancer Service Line. She has been an instrumental partner in shaping the cancer service line vision, critical to the successful launch of numerous institute-wide care pathways and initiatives that have changed the landscape for how cancer care is delivered within HFHS. Since 2018, she has also served as the Administrative Director for the Henry Ford Pancreatic Cancer Center, responsible for implementing a program structure that helps establish international research partnerships while helping to bring together a cohesive and robust internal HFHS pancreatic cancer research team.

Medical Oncology

Gadgeel Shirish 20 HFMGlogoShirish Gadgeel, M.D.
Division Head, Hematology/Oncology, Henry Ford Cancer Institute
Interim Deputy Director, Medical Oncology, Henry Ford Cancer Institute

Dr. Gadgeel is a highly respected researcher and Wayne State University professor, Dr. Gadgeel’s primary focus has been on research and drug development for lung cancer, leading or participating in multiple trials. Before joining Henry Ford, he served in multiple leadership roles including co-leading the Molecular Therapeutics Research Program of the Core Cancer Center Grant at Karmanos Cancer Institute and co-leader of the Thoracic Oncology Research Program as well as the Mary Lou Kennedy Research Professor of Thoracic Oncology at the University of Michigan. He serves on several editorial or service boards including the Lung Cancer Committee of Southwest Oncology Group.

Radiation Oncology

Benjamin Movsas, M.D.Benjamin Movsas, M.D.
Chair, Department of Radiation Oncology, Henry Ford Cancer Institute

Dr. Movsas is a nationally recognized expert in the field of radiation oncology, stereotactic radiosurgery, lung cancer, prostate cancer, and quality of life issues pertaining to cancer. He has published extensively in many prestigious medical journals and regularly presents his research findings at some of the nation’s top medical meetings. Dr. Movsas holds leadership positions in the most prominent academic organizations, most recently as President of the American Society for Radiation Oncology (ASTRO) Society of Chairs of Academic Radiation Oncology Programs (SCAROP), and President-Elect of the American Radium Society.

Surgical Oncology

David S. Kwon, M.D.David S. Kwon, M.D.
Division Head, Surgical Oncology, Henry Ford Cancer Institute
Interim Deputy Director, Surgical Oncology, Henry Ford Cancer Institute

Dr. Kwon, serves as Physician in Charge at the Brigitte Harris Cancer Pavilion. Dr. Kwon has been at the forefront of design and implementation of Cancer Care Pathways. As chair of the HFCI Commission on Cancer committee, he recently oversaw the re-accreditation of cancer programs across all HFHS (CoC) hospitals, which received the highest honor available with an “Outstanding Achievement” award. Additionally, he also chairs the Surgical Innovations Committee for the AHPBA and serves on the Clinical Research Program Committee for the Alliance of Clinical Trials in Oncology. He has also served as a Michigan State Chair of the CoC since 2019 and is currently the treasurer for the Michigan chapter of the American College of Surgeons.

Dr. David Kwon is a board-certified surgeon and fellowship-trained surgical oncologist, His clinical interests include pancreatic cancer surgery and cytoreductive cancer surgery for HIPEC. Dr. Kwon received his undergraduate degree in Biological Sciences from Columbia University and earned his medical degree from the University of California, San Diego. He completed his residency in general surgery at Henry Ford Hospital where he received multiple research and clinical awards. He completed a surgical oncology fellowship at the University of Texas, M.D. Anderson Cancer Center where he developed clinical expertise in the multidisciplinary care of cancer patients.

Research

Margot LaPointe, Ph.D.Margot LaPointe, Ph.D.
Vice President of Research, Henry Ford Health System

Dr. LaPointe oversees the basic/translational, clinical and population/healthcare research at Henry Ford, as well an internal grant program, the clinical trials office and clinical research center, biostatistics core, research space, and the Department of Research Administration. She closely works with the Assistant Deans for Research at Wayne State University School of Medicine and the Wayne State University Vice President of Research. Dr. LaPointe received her degrees from Louisiana State University, the University of North Carolina, and the University Of New Orleans, LA. She completed her research fellowship at the University of California, San Francisco.

Precision Medicine & Clinical Trials

Tom Mikkelsen M.D.
Medical Director, Precision Medicine Program, and Clinical Trials Office

Dr. Mikkelsen is the medical director of the Precision Medicine Program, and the Clinical Trials Office, at the Henry Ford Cancer Institute. He has been part of the brain tumor program at Henry Ford Hospital for more than 25 years, founding the Hermelin Brain Tumor Center, and building the clinical trials program, and laboratory of tumor biology.

Under Dr. Mikkelsen’s leadership, the Hermelin Brain Tumor Center has become a trailblazer in the understanding of the genetics of brain tumors, and in the development of therapies matched to each patient's brain tumor genetics. The center is a major contributor to The Cancer Genome Atlas -- a national cooperative of major academic medical centers sponsored by the National Institutes of Health, responsible for identifying certain survival-related genes.

He is internationally recognized in neuro-oncology and precision medicine, which develops personalized medicine treatment options for patients - in cancer and other areas.

Dr. Mikkelsen received his MD from the University of Calgary, Canada, and completed clinical training in neurology at the Montreal Neurologic Institute. In addition, he did post-doctoral training in tumor and molecular biology at the Ludwig Institute for Cancer Research in Montreal, and La Jolla, California.

Supportive Oncology Services

Michael Ryan, PSYD, Michael Ryan, PSYD
Clinical Director, Supportive Oncology Services, Henry Ford Cancer Institute

Dr. Ryan specializes in the care of cancer patients and their caregivers from diagnosis through survivorship.She graduated with her Doctorate in Clinical Psychology from the Florida School of Professional Psychology in Tampa, Florida. She completed her internship and fellowship training in Clinical Health Psychology at Henry Ford Hospital where she joined as a senior staff psychologist with the Henry Ford Cancer Institute in 2011.






Connect with our Cancer Team 24/7

Call us at (888) 777-4167.

Schedule Appointment Online

Please call 911 if you have an emergency or urgent medical question.

If you are having symptoms of COVID-19, for your safety, please select a MyChart video visit on demand or call your primary care provider. For symptoms of COVID-19, please visit our website www.henryford.com/coronavirus.

Henry Ford Health System is committed to ensuring our Deaf or hard-of-hearing patients and visitors have equal access to all services. We provide the appropriate auxiliary aids and services, including qualified sign language interpreters, TTYs and other assistive listening devices, at no cost. To request assistance, call 313-916-1896 or email [email protected].

Schedule Appointment for